Article
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2021
McGrail D J, Pilié P G, Rashid N U, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger A B, Lim B, Ueno N T, Litton J K, Ferrarotto R, Chang J T, Moulder S L, Lin S-Y
Abstract excerpt
BACKGROUND: High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer approval of ICB treatment for any TMB-H tumor, as assessed by the targeted FoundationOne CDx assay in nine tumor types, the utility of this biomarker has not been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.